In Taiwan, hematopoietic SCT (HSCT) has been used to treat patients with hematological diseases since 1983. Since then, more than 2200 patients have undergone HSCT in 15 large hospitals. The disease entities included acute leukemia in 37% of cases, non-Hodgkin's lymphoma in 26%, CML in 10%, multiple myeloma in 7% and severe aplastic anemia in 6%. The conditioning regimens used were mainly myeloablative (84% of cases). Nonmyeloablative regimens were fludarabine-based. The average age of allogeneic recipients was at least 10 years older than those in the era before their application. The grafts of all patients were derived from peripheral blood in 85% of cases, BM in 13% and cord blood (CB) in 2%. Forty percent of HSCT patients received autologous grafts, whereas more than 25% of allogeneic HSCT patients received grafts from unrelated donors, and overall, there were more than 200 Taiwan HSCT recipients. Currently, CB has been used successfully in pediatric patients with thalassemia major and also in adult patients with hematological malignancy. After transplantation, there was a relatively lower prevalence of acute GVHD. However, a relatively higher proportion of hepatitis B carriers in the recipients had led to a higher incidence of viral reactivation and clinical hepatitis, which was dramatically decreased following lamivudine prophylaxis. In conclusion, HSCT has been successfully adapted to routine clinical care in Taiwan. Several important findings contributing to the progress of HSCT in the past two decades have also been noticed on this island.
Introduction
Taiwan, formerly Formosa, is situated in the western Pacific between temperate Japan to the north, tropical Philippines to the south and subtropical southern China to the west. It geographically covers the island of Taiwan proper, as well as Penghu, Kinmen, Matsu and other outlying islands, with 22.8 million people living in an area of about 36 000 km 2 . The population is concentrated on the western coast around the metropolitan areas of Taipei in the north, Taichung in the center and Kaohsiung in the south. The ethnical composition of Taiwan included two groups: an indigenous minority of Austronesian origin, which now makes up roughly two percent of the population, and a Han majority composed of people whose ancestors came in two large waves from China, one beginning in the 17th century and the other after 1949. In recent years, an increase in marriages between the people of Taiwan and citizens from other nations, as well as an influx of guest workers from Southeast Asia, has made Taiwan an even more pluralistic society. 1 
Transplantation centers and activities
In Taiwan, hematopoietic SCT (HSCT) has been used to treat patients with hematological diseases since 1983, mainly in two hospitals of North Taiwan, Taipei Veterans General Hospital (Taipei VGH) and National Taiwan University Hospital (NTUH). The number of hospitals performing HSCT is progressively increased in recent years, and at the end of 2006 there were at least 15 hospitals with more than 200 recipients per year in Taiwan. Up to now, there were more than 2200 patients who had undergone HSCT, among which over 80% of cases were performed in these two hospitals of North Taiwan described above.
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Characteristics of HSCT recipients and donors in Taiwan
During the survey in 2005, the disease entities of HSCT patients included AML in 26% of cases, non-Hodgkin's lymphoma in 26%, ALL in 11%, CML in 10%, multiple myeloma in 7%, severe aplastic anemia in 6% with the remaining 14% including Hodgkin's disease, myelodysplastic syndrome and inherited genetic/metabolic diseases. At present, the number of CML patients receiving HSCT has been decreased after the application of BCR-ABR targeted therapy, that is, gleevic as frontline treatment of CML, whereas the number of multiple myeloma patients has been increased.
The conditioning regimens used in Taiwan were mainly myeloablative in 84% of cases during the survey in 2005 and were individualized depending on different disease entities. Since 1999, we have started to use non-myeloablative (NST) or reduced-intensity regimens in elderly or poor performance status patients with different hematological malignancies. 5 Most of these regimens used are fludarabine-based, depending on different disease entities. Following the increasing application of NST, the average age of allogeneic recipients was at least 10 years older than those in the era before its application (unpublished data). In addition, i.v. BU is also commonly used and replaced the oral BU as the conditioning regimens in pediatric patients or those patients with poor compliance on oral medications. 6 Forty percent of HSCT recipients received autologous grafts, mainly for those with multiple myeloma and nonHodgkin's lymphoma, whereas the remaining 60% of HSCT were allogeneic transplantations. The grafts of all patients were derived from PBSC in 85% of cases, BM in 13 % and cord blood (CB) in 2%. Currently, the number of Taiwanese patients using BM graft is decreasing, mainly in pediatric patients and those with non-malignant hematologic diseases. In Taiwan, using PBSC as the graft had been started earlier in the mid-1990s. 7 Along with the increasing number of cases using PBSC grafts from matched-related donors, the long-term safety of allogeneic PBSCT was established. Finally, the allogeneic PBSCT was applicable from unrelated donors registering in the Tzu Chi Bone Marrow Donor Registry (TCBMDR) after a long debate in Taiwan (see below) .
At present, more than twenty-five percent of the grafts are derived from unrelated donors and the ratio is increasing from day to day in Taiwan. The first unrelated BMT was performed in Taipei VGH with the graft from Hong Kong BMDR in 1993. Thereafter, except for a few cases, almost all of the unrelated donors were provided by TCBMDR. The registry was established in 1994 and had collected data from over 200 000 volunteer donors by the end of 2002. 8, 9 The estimated matching rate is about 50-60% in our population, and more than 200 Taiwanese HSCT recipients were successfully matched. The rapid economic and political transformation in Taiwan over the past two decades has led to a rapid reduction of total fertility rate (the average number of children born to a woman during her childbearing years), which was five during the 1960s, dropped to two in the 1980s and declined even more to 1.18 in 2004.
1 Therefore, the increasing use of more unrelated donors will be expected in the future.
Earlier, in the mid-late 1990s, CB was initially used as a graft in several pediatric patients in NTUH (Dr. Kai-Hsin Lin for most of the cases) and in Taipei VGH. The disease entities included acute leukemia, severe aplastic anemia and mucopolysaccharidosis. It has now been successfully applied in pediatric recipients with thalassemia major. 10 On the other hand, the use of CB in adult patients or those with a higher body weight was not initiated till 2004, especially the use of dual-unit CB. [11] [12] [13] The source of CB comes from non-profit banks for example, TCBMDR and Koo Foundation Sun Yat-Sen Cancer Center, and other profit banks such as the StemCyte Cord Blood Bank and so on. CB transplantation was approved only in clinical trials before 2006, and presently the number of cases has been increasing in the last 2 years.
Lower prevalence of acute GVHD
According to the earlier analysis, the rate of post-transplant complications was similar, except for a lower rate (less than 10%) of grades II-IV acute GVHD. 3, 4, 14 It might be possibly associated with the use of isolation rooms with laminar airflow and a relatively lower level of genetic diversity in histocompatible antigens. The observation will be further validated by a large scale of survey.
Endemic infections of hepatitis viruses and tuberculosis after HSCT
In earlier observations of our group, up to 80% of Taiwanese HSCT patients had abnormal liver function tests after transplantation, [15] [16] [17] and a large proportion of cases were related to hepatitis virus infections, especially hepatitis B virus (HBV). [18] [19] [20] The complication was mainly a consequence of the fact that Taiwan is one of the endemic areas for HBV infection, with 15% of surface antigen (HBsAg) carrier rate in the general population. We found that up to 50% of Taiwanese HSCT recipients had altered HBV markers 3-12 months after BMT, including seroconversion of HBsAg, clearance of HBsAb, appearance of HBeAg, clearance of HBeAb and acute hepatitis. 18 More importantly, allogeneic HSCT HBsAg-positive recipients had a higher risk of these events than of autologous ones, including the risk of fulminant hepatitis and death. 20 Fortunately, extended lamivudine therapy (which is given early before transplantation, usually at the beginning of conventional chemotherapy) was used and the occurrence of post-transplant HBV-related hepatitis was significantly decreased. 21 Meanwhile, we demonstrated that lamivudineresistant mutations were frequently detected in 63% of patients during therapy and that at least 27% of cases had recurrence of HBV infection. At present, the proper timing to withdraw lamivudine is not well defined, and, in addition, we begin to focus on the majority of our patients, that is, HBsAg-negative recipients, to find out the risk factors and possible pathogenesis of reverse seroconversion. 18, 22 For tuberculosis (TB) infection, Tang and colleagues 23 at NTUH found that there were eight patients with pulmonary TB over a 6-year period in a retrospective study of 350 HSCT recipients. Four cases were fatal and they were found to have an obviously shorter duration between HSCT and the onset of infection. All the eight patients with pulmonary TB received allogeneic HSCT and most (seven of eight patients) developed the infection during treatment for GVHD. They estimated that the relative risk of having pulmonary TB after HSCT was 13.1-fold higher than that for the general population in Taiwan.
Cost and insurance coverage of HSCT
Most of the cost for HSCT performed in Taiwan has been reimbursed by the National Health Insurance (NHI) in the past 12 years. The average cost of each case, including conditioning, acute GVHD prophylaxis, isolation room, graft harvest, blood products and other medications within 30 days after transplant is around new Taiwan dollar (NTD) 1 000 000 dollars for allogeneic transplant (estimated at USD 30 000) and 600 000 NTD (USD 18 000) for autologous transplant. In view of the rapidly growing cost of health care and the increasing number of the elderly population, the government launched the NHI program on 1 March 1995 to provide universal medical care for the whole society. By the end of 2005, 22 314 647 people were covered by the NHI program and over 90 percent of the medical institutions in Taiwan, 17 931 in total, had joined the NHI care system. 1 For new agents used in HSCT, applications should be made by physicians to the bureau of NHI before the procedure is performed. However, if the grafts are from unrelated donors or CB, the expenses to cover the donor as well as the graft should be co-shared by recipients.
Participation in international registries
Along with clinical practices, several hospitals that underwent HSCT in Taiwan have also participated in some international registries, including International Bone Marrow Transplant Registry (IBMTR) earlier and European Bone Marrow Transplantation (EBMT) Registry lately. In recent years, the upsurge of Asian Cord Blood and Asia-Pacific Blood and Marrow Transplantation has motivated the models in the registration system and cooperative study. In this field, Taiwan is one of the core members of these two Asian groups.
Research activities in transplantation
Since the mid-1990s, HLA-mismatched allogeneic BMT, including those with haploidentical donor [24] [25] [26] and donor lymphocyte infusion, 27 was investigated and, at present, they have been well adopted in clinical practice. The role of prophylactic donor lymphocyte infusion is also under study. In addition, our group also emphasized early the favorable benefit of pulmonary function in patients receiving non-myeloablative conditioning. 28 CB transplantation is widely used to rescue more children with thalassemia major nowadays. 10 The study of HBV infection in HSCT recipients is continuously moved to HBsAgnegative patients by our group, as described above.
Conclusions
In Taiwan, HSCT has been successfully used as routine care in clinical practice for some patients with hematological disorders and there have been several important findings that have contributed to the progress of HSCT in the past more than two decades. With the increasing number of patients and hospitals involved in HSCT activities, a variety of cooperative groups have been established not only for physicians, including the registry, research and transfer, but also for patients, including patient supportive systems.
